FDA Brief

Warning letters Drugs

FDA warning letter to

Empower Clinic Services, LLC dba Empower Pharmacy

High riskIssued Apr 2, 2025Posted Apr 29, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Empower Pharmacy that insanitary conditions in sterile drug compounding put patients at risk.

What happened

FDA inspected the Houston facility from September 24 to October 4, 2024, and issued a Form FDA 483, FDA's list of inspection observations, on October 4, 2024. FDA said investigators found serious deficiencies in sterile drug production: environmental monitoring did not sample the critical filling area, media fills were not run under worst-case conditions, and equipment in the ISO 5 (high-cleanliness) area was not properly sterilized. FDA reviewed the company's responses dated October 28, 2024, and January 31, 2025, and said some corrective actions were incomplete or lacked enough documentation.

What FDA found

  1. FDA cited the firm for not adequately monitoring air in the critical filling area where sterile drugs are exposed.

    FDCA section 501(a)(2)(A), 21 U.S.C. § 351(a)(2)(A)
  2. FDA cited the firm because its media fills (test runs using growth medium instead of drug) were not performed under the most challenging conditions, so it lacked assurance of aseptic (sterile) production.

    FDCA section 501(a)(2)(A), 21 U.S.C. § 351(a)(2)(A)
  3. FDA cited the firm for not properly sterilizing the stopper sorting bowl, supply hopper, and insertion station in the ISO 5 area that contact stoppers used for injectable drugs.

    FDCA section 501(a)(2)(A), 21 U.S.C. § 351(a)(2)(A)

What FDA wants

FDA asks the company to respond in writing within 15 working days with specific corrective steps, an explanation of how it will prevent recurrence, and supporting documents. FDA also strongly recommends a comprehensive assessment of operations, including aseptic processing, with a third-party sterile manufacturing expert.

Who should pay attention

  • patients and clinics that receive compounded sterile injectables from this pharmacy
  • compounding pharmacies and sterile manufacturers with similar aseptic operations
  • healthcare providers who prescribe or administer compounded injectable drugs

This is a summary. Read the original letter on fda.gov.

Empower Clinic Services, LLC dba Empower Pharmacy's FDA history

  1. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warned Empower Pharmacy over unapproved compounded semaglutide/tirzepatide copies and sterile manufacturing deficiencies that put patients at risk.

    High risk
  2. Empower Clinic Services, LLC dba Empower Pharmacy

    FDA warns Empower Pharmacy its compounded drugs missed outsourcing-facility conditions, including labeling and adverse-event reporting.

    Medium

Full company page

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk